Prostaglandins were discovered to be products of arachidonic acid and with the ability to radio label arachidonic acid in the early 1960s, American chemist E.J. Corey was able to synthesize prostaglandin E2 in the lab in the 1970. This advancement paved the way for later studies that helped define the actions and response of prostaglandin E2. Prostaglandin E2 was approved for medical use in the United States in 1977 and it is on the World Health Organizations List of Essential Medicines. Prostaglandin E2 was approved by the FDA in 1977. References
External links
"Dinoprostone". Drug Information Portal. U.S. National Library of Medicine.
Oral formulation
An oral formulation has been marketed and registered in most European countries. It has similar efficacy as the intravenous formulation, but it avoids venous toxicities of an infusion and is easier to take. The oral form is not approved in the United States, or Australia. References
External links
"Vinorelbine". Drug Information Portal. U.S. National Library of Medicine.